# A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

> **NCT03070990** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 19 (actual)

## Conditions studied

- Metastatic Urothelial Cancer

## Interventions

- **DRUG:** Enfortumab vedotin

## Key facts

- **NCT ID:** NCT03070990
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-24
- **Primary completion:** 2019-02-25
- **Final completion:** 2019-02-25
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03070990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03070990, "A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03070990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*